itraconazole
itraconazole: 38 clinical trials tracked.
itraconazole evidence translation
What we can confirm
38 tracked trials
What it means
What to watch
Prepared research question
What is verified about itraconazole, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 12 study sponsors
Related indications
Clinical Trial Registry Records (38)showing 10 most recent
The Drug-Drug Interaction Study of Clifutinib
Primary endpoint: Cmax
Optimizing Azole Therapy in Chronic Pulmonary Aspergillosis: A Randomized Comparative Study of Itraconazole and Posaconazole Integrating Clinical Outcomes, Azole Exposure, and Resistance Surveillance
Primary endpoint: Overall favorable treatment response at 12 months
A Phase 1, Two-part, Open-label, Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
Primary endpoint: Part 1 and 2: Maximum observed plasma concentration (Cmax) of pelabresib
A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants
Primary endpoint: Maximum observed concentration (Cmax) of Navlimetostat
A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of ABBV-932 in Adult Subjects With Bipolar Disorder
Primary endpoint: Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCAR
An Open-label, Randomised, Two Arm, Fixed Sequence Study in Healthy Participants to Assess the Pharmacokinetics of AZD4144 When Administered Alone and in Combination With Itraconazole
Primary endpoint: Area under concentration time curve from time 0 to infinity (AUCinf)
An Open-label, Phase 1 Study to Individually Characterize the Food Effect, the Drug-Drug Interaction Effect of OAT Inhibition, and the Drug-Drug Interaction Effect of P-glycoprotein Inhibition on the Pharmacokinetics of MK-8527 in Healthy Adult Participants
Primary endpoint: Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food
A Phase 1 Open-Label, Two-Period Study to Evaluate the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of Nacresertib in Healthy Adult Subjects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Nacresertib
An Open-Label, Parallel Group Study Designed to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
Primary endpoint: Part A and Part B: Time of the Maximum Observed Concentration (Tmax) of BGB-58067
A Phase 1, Open-Label, Fixed-Sequence Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of LY4395089 in Healthy Participants
Primary endpoint: Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from 0 to infinity (AUC[0-∞]) of LY4395089